Arrowhead Research Corporation (Public, NASDAQ:ARWR) literally doubled from
around 0.50 to over 1.25 on Monday of this week.
Might be one to watch in the weeks and months to come.

Here's the background:

Arrowhead Research Corporation's Subsidiary Provides First Proof Of RNA
Interference In Humans with Systemically Administered siRNA Therapeutic
Monday, 22 Mar 2010 06:00am EDT
Arrowhead Research Corporation announced that the clinical trial being conducted
by majority owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated
systemic delivery of siRNA and the successful silencing of a widely recognized
cancer gene via RNA interference (RNAi) in humans. This represents a
breakthrough for Calando, its proprietary RONDEL delivery system, and the field
of RNAi. It is thought to be the first ever demonstration in humans of targeted
siRNA-containing nanoparticle delivery to tumors using systemic administration,
delivery of functional siRNAs, and achievement of specific mRNA and protein
reductions via RNAi. Thus far in the trial, no significant drug-related
toxicities, known as serious adverse events (SAEs), have been observed that may
limit use. The trial, which is investigating the safety and efficacy of drug
candidate CALAA-01 and the broader RONDEL nanoparticle delivery system,
represented the first time siRNA was systemically administered using a delivery
system and the first use of siRNA against cancer in humans.